Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.87 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.69 |
| ▸ | GAA | P10253 | 1/20 | 0.63 |
| ▸ | TSHR | P16473 | 1/20 | 0.63 |
| ▸ | LMNA | P02545 | 1/20 | 0.59 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.59 |
| ▸ | CFTR | P13569 | 1/20 | 0.58 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.58 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.58 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.58 |
| ▸ | GOPC | Q9HD26 | 1/20 | 0.58 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.50 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.49 |
| ▸ | BRD4 | O60885 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.46 |
| ▸ | KCNA5 | P22460 | 2/20 | 0.46 |
| ▸ | KCNN4 | O15554 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30476552 | 0.93 | SMN1; SMN2 (1.00) | SMN1; SMN2CYP17A1GAATSHRLMNA | |
| SCHEMBL28001042 | 0.93 | SMN1; SMN2 (1.00) | SMN1; SMN2CYP17A1GAATSHRLMNA | |
| SCHEMBL30476558 | 0.93 | SMN1; SMN2 (1.00) | SMN1; SMN2CYP17A1GAATSHRLMNA | |
| SCHEMBL477633 | 0.93 | SMN1; SMN2 (1.00) | SMN1; SMN2CYP17A1GAATSHRLMNA | |
| SCHEMBL477393 | 0.93 | SMN1; SMN2 (1.00) | SMN1; SMN2CYP17A1GAATSHRLMNA | |
| SCHEMBL18228789 | 0.91 | SMN1; SMN2 (0.81) | SMN1; SMN2CYP17A1GAATSHRLMNA | |
| SCHEMBL11062714 | 0.88 | CYP17A1 (0.90) | SMN1; SMN2CYP17A1GAATSHRLMNA | |
| SCHEMBL8438887 | 0.87 | SMN1; SMN2 (0.68) | SMN1; SMN2CYP17A1GAATSHRLMNA | |
| SCHEMBL745419 | 0.86 | SMN1; SMN2 (0.72) | SMN1; SMN2CYP17A1GAATSHRLMNA | |
| SCHEMBL2908868 | 0.86 | SMN1; SMN2 (0.72) | SMN1; SMN2CYP17A1GAATSHRLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 73 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4665718-A1 | SMALL MOLECULES AS MONOACYLGLYCEROL LIPASE (MAGL) INHIBITORS, COMPOSITIONS AND USE THEREOF | Apogee Pharmaceuticals, Inc. (CA) | 2025-12-24 | — | — | EP | disclosed |
| US-12378231-B2 | Small molecules as monoacylglycerol lipase (MAGL) inhibitors, compositions and use thereof | APOGEE PHARMACEUTICALS, INC. (CA) | 2025-08-05 | — | — | US | disclosed |
| US-20240294514-A1 | SMALL MOLECULES AS MONOACYLGLYCEROL LIPASE (MAGL) INHIBITORS, COMPOSITIONS AND USE THEREOF | APOGEE PHARMACEUTICALS, INC. (CA) | 2024-09-05 | — | — | US | disclosed |
| WO-2024168426-A1 | SMALL MOLECULES AS MONOACYLGLYCEROL LIPASE (MAGL) INHIBITORS, COMPOSITIONS AND USE THEREOF | APOGEE PHARMACEUTICALS, INC. (CA) | 2024-08-22 | — | — | WO | disclosed |
| US-12018004-B2 | Carbamate compounds and methods of making and using same | H. LUNDBECK A/S (DK) | 2024-06-25 | — | — | US | disclosed |
| US-20230312499-A1 | CARBAMATE COMPOUNDS AND METHODS OF MAKING AND USING SAME | H. LUNDBECK A/S (DK) | 2023-10-05 | — | — | US | disclosed |
| US-20230312499-A1 | CARBAMATE COMPOUNDS AND METHODS OF MAKING AND USING SAME | H. LUNDBECK A/S (DK) | 2023-10-05 | — | — | US | disclosed |
| US-20230312499-A1 | CARBAMATE COMPOUNDS AND METHODS OF MAKING AND USING SAME | H. LUNDBECK A/S (DK) | 2023-10-05 | — | — | US | disclosed |
| US-11530189-B2 | Carbamate compounds and methods of making and using same | H. LUNDBECKA/S (DK) | 2022-12-20 | — | — | US | disclosed |
| US-11530189-B2 | Carbamate compounds and methods of making and using same | H. LUNDBECKA/S (DK) | 2022-12-20 | — | — | US | disclosed |
| EP-1981508-A2 | POTASSIUM CHANNEL INHIBITORS | Merck & Co., Inc. (US) | 2008-10-22 | — | — | EP | disclosed |
| US-20080090794-A1 | Potassium Channel Inhibitors | MERCK SHARP & DOHME LLC | 2008-04-17 | — | — | US | disclosed |
| WO-2007089743-A3 | POTASSIUM CHANNEL INHIBITORS | MERCK & CO INC (US) | 2007-12-13 | — | — | WO | disclosed |
| WO-2007089743-A2 | POTASSIUM CHANNEL INHIBITORS | MERCK & CO., INC. (US) | 2007-08-09 | — | — | WO | disclosed |
| EP-1781635-A2 | POTASSIUM CHANNEL INHIBITORS | Merck & Co., Inc. (US) | 2007-05-09 | — | — | EP | disclosed |
| WO-2006015159-A2 | POTASSIUM CHANNEL INHIBITORS | MERCK & CO., INC. (US) | 2006-02-09 | — | — | WO | disclosed |
| US-5405843-A | Anticancer drug potentiators | MITSUI TOATSU CHEMICALS, INCORPORATED (JP) | 1995-04-11 | — | — | US | disclosed |
| EP-0363212-B1 | Novel heterocyclic compounds and anticancer-drug reinforcing agents containing them as effective components | MITSUI TOATSU CHEMICALS (JP) | 1995-01-04 | — | — | EP | disclosed |
| US-5204348-A | Quinoline derivatives | MITSUI TOATSU CHEMICALS INC. (JP) | 1993-04-20 | — | — | US | disclosed |
| US-5112817-A | Anticancer Drug Potentiators | MITSUI TOATSU CHEMICALS, INCORPORATED (JP) | 1992-05-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11530189-B2 | Carbamate compounds and methods of making and using same | ABHD6, ABHD16A, RABL6 | SMN1; SMN2 2374/4885CYP17A1 4291/4885GAA 742/4885 |
| US-20080090794-A1 | Potassium Channel Inhibitors | KCNJ2, KCNQ2, KCNH2 | SMN1; SMN2 4477/4885CYP17A1 3931/4885GAA 3707/4885 |
| US-12378231-B2 | Small molecules as monoacylglycerol lipase (MAGL) inhibitors, compositions and use thereof | MGLL, PNLIP, LPL | SMN1; SMN2 502/4885CYP17A1 1396/4885GAA 31/4885 |
| US-20230312499-A1 | CARBAMATE COMPOUNDS AND METHODS OF MAKING AND USING SAME | ABHD6, ABHD16A, RABL6 | SMN1; SMN2 2374/4885CYP17A1 4291/4885GAA 742/4885 |
| US-20240294514-A1 | SMALL MOLECULES AS MONOACYLGLYCEROL LIPASE (MAGL) INHIBITORS, COMPOSITIONS AND USE THEREOF | MGLL, PNLIP, LPL | SMN1; SMN2 502/4885CYP17A1 1396/4885GAA 31/4885 |
| US-12018004-B2 | Carbamate compounds and methods of making and using same | ABHD6, ABHD16A, RABL6 | SMN1; SMN2 2374/4885CYP17A1 4291/4885GAA 742/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.